A Phase 1, Randomized, Open-label, Crossover Study to Assess Food Effect on Single Oral Dose Administration of TAK-385 Final Formulation in Premenopausal Healthy Adult Women
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Relugolix (Primary)
- Indications Endometriosis; Prostate cancer; Solid tumours; Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Takeda
- 06 Sep 2016 Status changed from active, no longer recruiting to completed.
- 18 Aug 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 03 Jun 2016 New trial record